nach oben

Erschienen in:

24.05.2021 | Original Article

Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma

verfasst von: Lulu Liu, Ruyi Zhang, Jingwen Deng, Xiaomeng Dai, Xudong Zhu, Qihan Fu, Hangyu Zhang, Zhou Tong, Peng Zhao, Weijia Fang, Yi Zheng, Xuanwen Bao

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Liver cancer accounts for 6% of all malignancies causing death worldwide, and hepatocellular carcinoma (HCC) is the most common histological type. HCC is a heterogeneous cancer, but how the tumour microenvironment (TME) of HCC contributes to the progression of HCC remains unclear. In this study, we investigated the immune microenvironment by multiomics analysis. The tumour immune infiltration characteristics of HCC were determined at the genomic, epigenetic, bulk transcriptome and single-cell levels by data from The Cancer Genome Atlas portal and the Gene Expression Omnibus (GEO). An epigenetic immune-related scoring system (EIRS) was developed to stratify patients with poor prognosis. SPP1, one gene in the EIRS system, was identified as an immune-related predictor of poor survival in HCC patients. Through receptor-ligand pair analysis in single-cell RNA-seq, SPP1 was indicated to mediate the crosstalk between HCC cells and macrophages via SPP1-CD44 and SPP1-PTGER4 association. In vitro experiments further validate SPP1 can trigger the polarization of macrophages to M2-phenotype tumour-associated macrophages (TAMs).

Nur mit Berechtigung zugänglich

Center MM, Jemal A (2011) International trends in liver cancer incidence rates. Cancer Epidemiol Prev Biomark 20(11):2362–2368CrossRef

Greten TF, Sangro B (2018) Targets for immunotherapy of liver cancer. J Hepatol 68(1):157–166CrossRef

Elsegood CL, Tirnitz-Parker JE, Olynyk JK, Yeoh GC (2017) Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma. Clini Trans Immunol 6(11):e161CrossRef

Lu L, Jiang J, Zhan M, Zhang H, Wang QT, Sun SN, et al. (2020) Targeting neoantigens in hepatocellular carcinoma for immunotherapy: A futile strategy? Hepatology 73(1):414–421

Löffler MW, Mohr C, Bichmann L, Freudenmann LK, Walzer M, Schroeder CM et al (2019) Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genom Med 11(1):1–16CrossRef

Bao X, Zhang H, Wu W, Cheng S, Dai X, Zhu X et al (2020) Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy. J Immunother Cancer 8(2):e001437CrossRef

Bao X, Shi R, Zhao T, Wang Y, Anastasov N, Rosemann M et al (2020) Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC. Cancer Immunol Immunother 70(1):189–202CrossRef

Bao X, Shi R, Zhao T, Wang Y (2020) Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma. Mol Oncol 14(5):917–932CrossRef

Bao X, Shi R, Zhao T, Wang Y (2020) Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma. J Mol Med 98:805–818

10.

Dai X, Guo Y, Hu Y, Bao X, Zhu X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P, Fang W (2021) Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics 11(7):3489–3501. https://doi.org/10.7150/thno.54648

11.

Bao X, Shi R, Zhao T, et al (2021) Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC[J]. Cancer Immunol Immunotherapy 70(1):189–202

12.

Bruni D, Angell HK, Galon J (2020) The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer 20(11):662-680CrossRef

13.

Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W et al (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4(1):1–11CrossRef

14.

Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA (2018) Profiling tumor infiltrating immune cells with CIBERSORT. Springer, Cancer Systems Biology, pp 243–259

15.

Hänzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14(1):7CrossRef

16.

Yu G, Wang L-G, Han Y, He Q-Y (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. Omics J Integr Biol 16(5):284–287CrossRef

17.

Wickham H (2016) ggplot2: elegant graphics for data analysis: Springer

18.

Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L et al (2012) VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22(3):568–576CrossRef

19.

Mayakonda A, Lin D-C, Assenov Y, Plass C, Koeffler HP (2018) Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 28(11):1747–1756CrossRef

20.

Smyth GK (2005) Limma: linear models for microarray data. Springer, Bioinformatics and computational biology solutions using R and Bioconductor, pp 397–420

21.

Hastie T, Qian J (2016) Glmnet vignette. Retriev June 2014(9):1–30

22.

Wolf FA, Angerer P, Theis FJ (2018) SCANPY: large-scale single-cell gene expression data analysis. Genome Biol 19(1):15CrossRef

23.

Efremova M, Vento-Tormo M, Teichmann SA, Vento-Tormo R (2019) Cell PhoneDB v2. 0: inferring cell-cell communication from combined expression of multi-subunit receptor-ligand complexes. BioRxiv. 563:680926

24.

Shi R, Bao X, Sun J, Lu S, Belka C, Li M (2020) Tumor microenvironment characterization in head and neck squamous carcinoma reveals distinct genomic alterations and clinical outcomes. Clin Trans Med 10(5):e187

25.

Bao X, Shi R, Zhang K, Xin S, Li X, Zhao Y et al (2019) Immune landscape of invasive ductal carcinoma tumour microenvironment identifies a prognostic and immunotherapeutically relevant gene signature. Front Oncol 9:903CrossRef

26.

Pages F, Galon J, Dieu-Nosjean M, Tartour E, Sautes-Fridman C, Fridman W (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29(8):1093–1102CrossRef

27.

Galon J, Angell HK, Bedognetti D, Marincola FM (2013) The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39(1):11–26CrossRef

28.

Melero I, Rouzaut A, Motz GT, Coukos G (2014) T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov 4(5):522–526CrossRef

29.

Bronger H, Singer J, Windmüller C, Reuning U, Zech D, Delbridge C et al (2016) CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br J Cancer 115(5):553–563CrossRef

30.

Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M (2005) The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 26(1):41–47PubMed

31.

Ding Q, Lu P, Xia Y, Ding S, Fan Y, Li X et al (2016) CXCL9: evidence and contradictions for its role in tumor progression. Cancer Med 5(11):3246–3259CrossRef

32.

de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Alifano M et al (2011) Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Can Res 71(20):6391–6399CrossRef

33.

Crotty S (2014) T follicular helper cell differentiation, function, and roles in disease. Immunity 41(4):529–542CrossRef

34.

Kowalczuk O, Burzykowski T, Niklinska WE, Kozlowski M, Chyczewski L, Niklinski J (2014) CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. Tumor Biol 35(5):4619–4628CrossRef

35.

Zhou S-L, Dai Z, Zhou Z-J, Chen Q, Wang Z, Xiao Y-S et al (2014) CXCL5 contributes to tumor metastasis and recurrence of intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils. Carcinogenesis 35(3):597–605CrossRef

36.

Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF (2019) WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res 25(10):3074–3083CrossRef

37.

Fedarko NS, Jain A, Karadag A, Fisher LW (2004) Three small integrin-binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J 18(6):734–736CrossRef

38.

Dalla-Torre CA, Yoshimoto M, Lee C-H, Joshua AM, de Toledo SR, Petrilli AS et al (2006) Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer 6(1):1–10CrossRef

39.

Sharon Y, Raz Y, Cohen N, Ben-Shmuel A, Schwartz H, Geiger T et al (2015) Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Can Res 75(6):963–973CrossRef

40.

Anborgh PH, Caria LB, Chambers AF, Tuck AB, Stitt LW, Brackstone M (2015) Role of plasma osteopontin as a biomarker in locally advanced breast cancer. Am J Transl Res 7(4):723PubMedPubMedCentral

41.

Zhang Y, Du W, Chen Z, Xiang C (2017) Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma. Exp Cell Res 359(2):449–457CrossRef

42.

Szulzewsky F, Pelz A, Feng X, Synowitz M, Markovic D, Langmann T et al (2015) Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS ONE 10(2):e0116644CrossRef

43.

Kijewska M, Kocyk M, Kloss M, Stepniak K, Korwek Z, Polakowska R et al (2017) The embryonic type of SPP1 transcriptional regulation is re-activated in glioblastoma. Oncotarget 8(10):16340CrossRef

44.

Klement JD, Paschall AV, Redd PS, Ibrahim ML, Lu C, Yang D et al (2018) An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. J Clin Investig 128(12):5549–5560CrossRef

Titel: Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma
verfasst von: Lulu Liu
Ruyi Zhang
Jingwen Deng
Xiaomeng Dai
Xudong Zhu
Qihan Fu
Hangyu Zhang
Zhou Tong
Peng Zhao
Weijia Fang
Yi Zheng
Xuanwen Bao
Publikationsdatum: 24.05.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 1/2022
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-021-02967-8

Springer Medizin

Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy

Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice

Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer

PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients

Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma

ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Update Onkologie